Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jul 29 · below the Ichimoku cloud · RSI 33 · MACD below its signal
| 17.40 | 52-week high | +52.10% |
| 14.78 | Previous month high | +29.20% |
| 12.99 | Previous month low | +13.55% |
| 12.26 | R3 (classic) | +7.14% |
| 12.18 | Previous week high | +6.47% |
| 12.06 | R2 (classic) | +5.45% |
| 11.87 | Previous day high | +3.76% |
| 11.75 | R1 (classic) | +2.72% |
| 11.56 | Pivot | +1.03% |
| 11.44 | Price now | |
| 11.36 | Previous day low | −0.66% |
| 11.34 | Previous week low | −0.87% |
| 11.25 | S1 (classic) | −1.69% |
| 11.05 | S2 (classic) | −3.38% |
| 10.74 | S3 (classic) | −6.10% |
| 7.14 | 52-week low | −37.63% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $7.4M | 0.01% | 475.92K | −8.2% | Q2 2026 |
| ARK Investment Management · Cathie Wood | $2.2M | 0.01% | 142.50K | −26% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a BWAY trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for BWAY.
TimeframesUp on the monthly, down on the hourly and daily, mixed on the weekly.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
over a rising 21 EMA, 21 over 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 22.9 | -1.0 | 14.9 | 24.6 | -4.0 | -2.4 | -1.8 | -4.7 | -9.1 | -13.3 | +20.3% | ||
| 2025 | 11.5 | -9.1 | -0.8 | -8.4 | 17.6 | 28.9 | -11.2 | 33.2 | -3.1 | 11.8 | 3.8 | 8.7 | +101.7% |
| 2024 | -3.4 | 3.5 | -18.4 | -0.8 | 19.8 | -3.5 | 19.3 | 9.3 | 16.8 | 8.2 | -1.3 | -4.5 | +45.5% |
| 2023 | -18.6 | -3.5 | -9.5 | -11.7 | 13.2 | 29.9 | 6.6 | 42.0 | 17.1 | -11.6 | 75.6 | 3.3 | +162.3% |
| 2022 | 0.6 | 0.3 | 12.3 | -12.1 | -6.8 | -32.4 | 27.3 | -31.0 | -15.0 | -2.8 | -46.0 | 30.3 | −67.9% |
| 2021 | 5.4 | 7.5 | 5.6 | -4.5 | 29.2 | -8.4 | -12.2 | -11.4 | 1.5 | 1.5 | -5.0 | -0.9 | +2.1% |
| 2020 | 15.4 | -5.9 | -25.0 | 7.7 | -8.8 | -24.1 | 0.5 | 31.9 | -25.7 | -4.2 | 15.8 | 16.5 | −22.7% |
| 2019 | -5.5 | 2.1 | -5.7 | 1.9 | -9.5 | -2.3 | 3.7 | 5.6 | −10.3% |
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Buy / hold / sell counts